Cosyntropin (ACTH (1–24)) is a synthetic peptide that is identical to the 24-amino acid segment at the N-terminal of adrenocorticotropic hormone. It is intended for use as a diagnostic agent in the screening of patients presumed to have adrenocortical insufficiency. Cosyntropin may bind to sites located on the adrenergic nerve endings associated with the cardiac tissue, and such binding would interfere with the neuronal reuptake of the catecholamines
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: Q01718 Gene ID: 4158.0 Gene Symbol: MC2R Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/2156274 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Diagnostic | CORTROSYN Approved UseCortrosyn™ (cosyntropin) for Injection is intended for use as a diagnostic agent in the screening of patients presumed to have adrenocortical insufficiency. Because of its rapid effect on the adrenal cortex it may be utilized to perform a 30-minute test of adrenal function (plasma cortisol response) as an office or outpatient procedure, using only 2 venipunctures (seeDOSAGE AND ADMINISTRATION section).
Severe hypofunction of the pituitary - adrenal axis is usually associated with subnormal plasma cortisol values but a low basal level is not per se evidence of adrenal insufficiency and does not suffice to make the diagnosis. Many patients with proven insufficiency will have normal basal levels and will develop signs of insufficiency only when stressed. For this reason a criterion which should be used in establishing the diagnosis is the failure to respond to adequate corticotropin stimulation. When presumptive adrenal insufficiency is diagnosed by a subnormal Cortrosyn™ test, further studies are indicated to determine if it is primary or secondary.
Primary adrenal insufficiency (Addison's disease) is the result of an intrinsic disease process, such as tuberculosis within the gland.
The production of adrenocortical hormones is deficient despite high ACTH levels (feedback mechanism). Secondary or relative insufficiency arises as the result of defective production of ACTH leading in turn to disuse atrophy of the adrenal cortex. It is commonly seen, for example, as result of corticosteroid therapy, Sheehan's syndrome and pituitary tumors or ablation.
The differentiation of both types is based on the premise that a primarily defective gland cannot be stimulated by ACTH whereas a secondarily defective gland is potentially functional and will respond to adequate stimulation with ACTH. Patients selected for further study as the result of a subnormal Cortrosyn™ test should be given a 3 or 4 day course of treatment with Repository Corticotropin Injection USP and then retested. Suggested doses are 40 USP units twice daily for 4 days or 60 USP units twice daily for 3 days. Under these conditions little or no increase in plasma cortisol levels will be seen in Addison's disease whereas higher or even normal levels will be seen in cases with secondary adrenal insufficiency. Launch Date1970 |
PubMed
Title | Date | PubMed |
---|---|---|
Adrenocorticotropin binding sites in rat cardiac tissue. | 1990 Jan |
|
Stress-related gene expression in brain and adrenal gland of porcine fetuses and neonates. | 2005 Mar 1 |
|
Subtyping of primary aldosteronism with adrenal vein sampling: Hormone- and side-specific effects of cosyntropin and metoclopramide. | 2018 Apr |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/pro/cortrosyn.html#s-34067-9
Cortrosyn™ (cosyntropin) for Injection may be administered intramuscularly or as a direct intravenous injection when used as a rapid screening test of adrenal function. It may also be given as an intravenous infusion over a 4 to 8 hour period to provide a greater stimulus to the adrenal glands. Doses of Cortrosyn™ 0.25 to 0.75 mg have been used in clinical studies and a maximal response noted with the smallest dose.
Route of Administration:
Other
Substance Class |
Protein
Created
by
admin
on
Edited
Sat Dec 16 00:25:59 GMT 2023
by
admin
on
Sat Dec 16 00:25:59 GMT 2023
|
Protein Sub Type | |
Sequence Type | COMPLETE |
Record UNII |
72YY86EA29
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000006478
Created by
admin on Sat Dec 16 00:25:59 GMT 2023 , Edited by admin on Sat Dec 16 00:25:59 GMT 2023
|
||
|
EU-Orphan Drug |
EU/3/18/2054
Created by
admin on Sat Dec 16 00:25:59 GMT 2023 , Edited by admin on Sat Dec 16 00:25:59 GMT 2023
|
||
|
NDF-RT |
N0000006478
Created by
admin on Sat Dec 16 00:25:59 GMT 2023 , Edited by admin on Sat Dec 16 00:25:59 GMT 2023
|
||
|
NDF-RT |
N0000006478
Created by
admin on Sat Dec 16 00:25:59 GMT 2023 , Edited by admin on Sat Dec 16 00:25:59 GMT 2023
|
||
|
FDA ORPHAN DRUG |
594017
Created by
admin on Sat Dec 16 00:25:59 GMT 2023 , Edited by admin on Sat Dec 16 00:25:59 GMT 2023
|
||
|
NCI_THESAURUS |
C1937
Created by
admin on Sat Dec 16 00:25:59 GMT 2023 , Edited by admin on Sat Dec 16 00:25:59 GMT 2023
|
||
|
FDA ORPHAN DRUG |
609817
Created by
admin on Sat Dec 16 00:25:59 GMT 2023 , Edited by admin on Sat Dec 16 00:25:59 GMT 2023
|
||
|
NDF-RT |
N0000006478
Created by
admin on Sat Dec 16 00:25:59 GMT 2023 , Edited by admin on Sat Dec 16 00:25:59 GMT 2023
|
||
|
WHO-ATC |
H01AA02
Created by
admin on Sat Dec 16 00:25:59 GMT 2023 , Edited by admin on Sat Dec 16 00:25:59 GMT 2023
|
||
|
NDF-RT |
N0000006478
Created by
admin on Sat Dec 16 00:25:59 GMT 2023 , Edited by admin on Sat Dec 16 00:25:59 GMT 2023
|
||
|
FDA ORPHAN DRUG |
545216
Created by
admin on Sat Dec 16 00:25:59 GMT 2023 , Edited by admin on Sat Dec 16 00:25:59 GMT 2023
|
||
|
NDF-RT |
N0000006478
Created by
admin on Sat Dec 16 00:25:59 GMT 2023 , Edited by admin on Sat Dec 16 00:25:59 GMT 2023
|
||
|
WHO-VATC |
QH01AA02
Created by
admin on Sat Dec 16 00:25:59 GMT 2023 , Edited by admin on Sat Dec 16 00:25:59 GMT 2023
|
||
|
NDF-RT |
N0000006478
Created by
admin on Sat Dec 16 00:25:59 GMT 2023 , Edited by admin on Sat Dec 16 00:25:59 GMT 2023
|
||
|
NDF-RT |
N0000175941
Created by
admin on Sat Dec 16 00:25:59 GMT 2023 , Edited by admin on Sat Dec 16 00:25:59 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
3307
Created by
admin on Sat Dec 16 00:25:59 GMT 2023 , Edited by admin on Sat Dec 16 00:25:59 GMT 2023
|
PRIMARY | |||
|
C28941
Created by
admin on Sat Dec 16 00:25:59 GMT 2023 , Edited by admin on Sat Dec 16 00:25:59 GMT 2023
|
PRIMARY | |||
|
3901
Created by
admin on Sat Dec 16 00:25:59 GMT 2023 , Edited by admin on Sat Dec 16 00:25:59 GMT 2023
|
PRIMARY | |||
|
CHEMBL2103784
Created by
admin on Sat Dec 16 00:25:59 GMT 2023 , Edited by admin on Sat Dec 16 00:25:59 GMT 2023
|
PRIMARY | |||
|
TETRACOSACTIDE
Created by
admin on Sat Dec 16 00:25:59 GMT 2023 , Edited by admin on Sat Dec 16 00:25:59 GMT 2023
|
PRIMARY | |||
|
2255
Created by
admin on Sat Dec 16 00:25:59 GMT 2023 , Edited by admin on Sat Dec 16 00:25:59 GMT 2023
|
PRIMARY | |||
|
2890
Created by
admin on Sat Dec 16 00:25:59 GMT 2023 , Edited by admin on Sat Dec 16 00:25:59 GMT 2023
|
PRIMARY | RxNorm | ||
|
m3809
Created by
admin on Sat Dec 16 00:25:59 GMT 2023 , Edited by admin on Sat Dec 16 00:25:59 GMT 2023
|
PRIMARY | Merck Index | ||
|
16960-16-0
Created by
admin on Sat Dec 16 00:25:59 GMT 2023 , Edited by admin on Sat Dec 16 00:25:59 GMT 2023
|
PRIMARY | |||
|
Adrenocorticotropic hormone (medication)
Created by
admin on Sat Dec 16 00:25:59 GMT 2023 , Edited by admin on Sat Dec 16 00:25:59 GMT 2023
|
PRIMARY | |||
|
16133751
Created by
admin on Sat Dec 16 00:25:59 GMT 2023 , Edited by admin on Sat Dec 16 00:25:59 GMT 2023
|
PRIMARY | |||
|
4516
Created by
admin on Sat Dec 16 00:25:59 GMT 2023 , Edited by admin on Sat Dec 16 00:25:59 GMT 2023
|
PRIMARY | |||
|
72YY86EA29
Created by
admin on Sat Dec 16 00:25:59 GMT 2023 , Edited by admin on Sat Dec 16 00:25:59 GMT 2023
|
PRIMARY | |||
|
72YY86EA29
Created by
admin on Sat Dec 16 00:25:59 GMT 2023 , Edited by admin on Sat Dec 16 00:25:59 GMT 2023
|
PRIMARY | |||
|
100000085201
Created by
admin on Sat Dec 16 00:25:59 GMT 2023 , Edited by admin on Sat Dec 16 00:25:59 GMT 2023
|
PRIMARY | |||
|
6965
Created by
admin on Sat Dec 16 00:25:59 GMT 2023 , Edited by admin on Sat Dec 16 00:25:59 GMT 2023
|
PRIMARY | |||
|
DTXSID201014470
Created by
admin on Sat Dec 16 00:25:59 GMT 2023 , Edited by admin on Sat Dec 16 00:25:59 GMT 2023
|
PRIMARY | |||
|
D003366
Created by
admin on Sat Dec 16 00:25:59 GMT 2023 , Edited by admin on Sat Dec 16 00:25:59 GMT 2023
|
PRIMARY | |||
|
241-031-1
Created by
admin on Sat Dec 16 00:25:59 GMT 2023 , Edited by admin on Sat Dec 16 00:25:59 GMT 2023
|
PRIMARY | |||
|
SUB10941MIG
Created by
admin on Sat Dec 16 00:25:59 GMT 2023 , Edited by admin on Sat Dec 16 00:25:59 GMT 2023
|
PRIMARY | |||
|
DB01284
Created by
admin on Sat Dec 16 00:25:59 GMT 2023 , Edited by admin on Sat Dec 16 00:25:59 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
MOL_WEIGHT:NUMBER(CALCULATED) | CHEMICAL |
|
||||
Molecular Formula | CHEMICAL |
|